Key clinical point: For patients undergoing TAVR, using a specific orientation at deployment may optimize valve alignment and potentially preserve coronary access, at least for some devices.
Major finding: Positioning the Evolut THV at a certain way at deployment led to an improvement in commissural alignment and a significant reduction in coronary artery overlap, while no such positioning effects were seen with the SAPIEN 3, and preliminary results with ACURATE-neo suggest a potential advantage to specific positionings at deployment.
Study details: A pilot imaging study including a total of 828 patients undergoing TAVR.
Disclosures: Study authors reported disclosures related to Boston Scientific, Edwards Lifesciences, and Medtronic, among others.
Tang GHL et al. JACC Cardiovasc Interv. 2020 Mar 16. doi: 10.1016/j.jcin.2020.02.005.